Document:

Document

Exhibit 4.2

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions of Delaware corporate law. You should read our certificate of incorporation and bylaws, which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended.
Our authorized capital stock consists of 170,000,000 shares of common stock and 2,000,000 shares of preferred stock. 

Common Stock

Holders of our common stock are entitled to one vote for each share held of record on all matters on which stockholders are generally entitled to vote. The majority of votes cast by the holders of shares entitled to vote on an action at a meeting at which a quorum is present is generally required to take stockholder action, unless a greater vote is required by law. Directors are elected by a plurality of the votes cast at any election and there is no cumulative voting of shares.
 
Holders of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available for the payment of dividends. Upon the liquidation, dissolution or winding up of the company, holders of common stock are entitled to share pro rata in any assets available for distribution to stockholders after payment of all obligations of the company and after provision has been made with respect to each class of stock, if any, having preference over the common stock. Holders of common stock do not have cumulative voting rights or preemptive, subscription or conversion rights and shares of common stock are not redeemable. The shares of common stock presently outstanding are duly authorized, validly issued, fully paid and non-assessable. There will be a prospectus supplement relating to any offering of common stock offered by this prospectus.
 
The directors of the company serve staggered three-year terms. Directors may not be removed without cause. The certificate of incorporation provides that the Board of Directors shall consist of such number of directors as shall be determined from time to time solely by resolution adopted by the affirmative vote of a majority of the voting power of the total number of directors then authorized.
 
Our certificate of incorporation and bylaws contain provisions that could have the effect of delaying, deterring or preventing a merger, tender offer or other takeover attempt. Our certificate of incorporation authorize the Board of Directors to issue up to 170 million shares of common stock (less shares already outstanding or reserved for issuance) and up to two million shares of preferred stock without stockholder approval. In addition, our certificate of incorporation provide that stockholder action without a meeting requires the unanimous consent of the stockholders, unless the applicable action has been approved by the Board of Directors prior to execution of the stockholder consent. Our bylaws permit incumbent directors to fill any vacancies on the Board of Directors, however occurring, whether by an increase in the number of directors, death, resignation, retirement, disqualification, removal from office or otherwise, unless filled by proper action of the stockholders. Furthermore, our bylaws require stockholders to give advance notice of director nominations and proposals to be presented at meetings of stockholders.
 
These provisions may delay stockholder actions with respect to business combinations and the election of new members to our Board of Directors. As such, the provisions could discourage open market purchases of our common stock because a stockholder who desires to participate in a business combination or elect a new director may consider them disadvantageous.

        

Subject to certain exceptions, Section 203 of the Delaware General Corporation Law prevents a publicly-held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our Board of Directors or unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger or consolidation involving us and the “interested stockholder” and the sale of more than 10% of our assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. We are currently not subject to Section 203 but may opt in at any time by amending our certificate of incorporation.
 
Listing
 
Our common stock is listed and traded on The Nasdaq Capital Market under the symbol “RMTI.”
 
Transfer Agent and Registrar
 
The transfer agent and registrar for our common stock is American Stock Transfer and Trust Company.
 
Preferred Stock
 
Our Board of Directors currently has the authority, without further action by our stockholders, to issue up to 2,000,000 shares of preferred stock, $0.001 par value per share, in one or more series and to fix the rights, preferences, privileges and restrictions thereof.  These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock.
 
The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation.  In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action.  No shares of preferred stock are currently outstanding.

    2EX-10.1

  Exhibit 10.1

   

   

   

   

   

  April 6, 2022

  Javier B. Szwarcberg, M.D., M.P.H.

  [***]

   

  Re: Amendment to Offer Letter

  Dear Javier,

  This letter agreement (this “Amendment”) amends the offer letter dated December 29, 2021 (the “Offer Letter”), between you and Spruce Biosciences, Inc. (the “Company”), as set forth below.

  The eighth paragraph of the Offer Letter is hereby amended and restated in its entirety as follows: 

  “You will be entitled to participate in the Company's Severance and Change of Control Plan (the "Severance Plan"), a copy of which will be separately provided to you, provided that with respect to the Second Stock Option only, the vesting acceleration benefits under the Severance Plan applicable to a Change in Control Termination (as defined in the Severance Plan) will only apply for a Change in Control (as defined in the Severance Plan) with an effective date on or after the first anniversary of your Start Date.”

  Other than as provided in this Amendment, the terms and conditions of your employment with the Company as set forth in the Offer Letter remain unchanged. This Amendment, together with the Offer Letter and the other plans, policies and agreements referred to therein, shall constitute the complete agreement between you and Company with respect to the terms and conditions of your employment. Further, the terms set forth herein supersede and replace any and all prior agreements or representations made to you concerning the subject matter hereof, whether written or oral.  This letter agreement cannot be modified, amended or extended except in a writing signed by you and a duly authorized officer of the Company.

   

  2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014

  

   

   

   

  Please acknowledge your acceptance of the modifications to the Offer Letter as set forth in this Amendment by signing and returning the original to the Company.

  Sincerely,

   

  /s/ Michael Grey			

  Michael Grey

  Spruce Biosciences, Inc.

  Accepted by:

  /s/ Javier B. Szwarcberg, M.D., M.P.H.	

  [signature]

  Javier B. Szwarcberg, M.D., M.P.H.    		

  [name]

  April 6, 2022                                        	

  Date

   

   

  2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014Exhibit 10.1

 

NINTH AMENDMENT TO LOAN AGREEMENT 

 

This NINTH AMENDMENT TO LOAN AGREEMENT (this "Amendment")
is made this as of the 5th day of April, 2022 by and among MidCap Business Credit LLC, a Texas limited liability company, the
secured party hereunder (hereinafter called “Lender”), BLONDER TONGUE LABORATORIES, INC., a Delaware corporation (together
with its successors and permitted assigns, “Borrower”), R. L. DRAKE HOLDINGS, LLC, a Delaware limited liability company
(together with its permitted successors and assigns, “Drake”), and BLONDER TONGUE FAR EAST, LLC, a Delaware limited
liability company (together with its permitted successors and assigns, “Far East”). Each of Borrower, Drake and Far
East are individually referred to herein as a “Loan Party” and individually, collectively, jointly and severally, the
“Loan Parties”.

 

WHEREAS, the Loan Parties and Lender have entered that
Loan and Security Agreement (All Assets) dated as of October 25, 2019, as amended by that certain Consent and Amendment to Loan Agreement
and Loan Documents, dated as of April 7, 2020, that certain Second Amendment to Loan Agreement, dated as of January 8, 2021, that certain
Third Amendment to Loan Agreement, dated as of June 14, 2021, that certain Fourth Amendment to Loan Agreement, dated as of July 30, 2021,
that certain Fifth Amendment to Loan Agreement, dated as of August 2, 2021, that certain Sixth Amendment to Loan Agreement, dated as of
December 15, 2021, that certain Seventh Amendment to Loan Agreement, dated as of February 11, 2022 and that certain Eight Amendment to
Loan Agreement, dated as of March 3, 2022 (as amended, the “Loan Agreement”).

 

WHEREAS, Borrower has requested that the Loan Agreement
be amended as provided herein, and Lender is willing to make such modifications to the Loan Agreement, subject to the terms and conditions
set forth herein.

 

NOW THEREFORE, in consideration of the foregoing premises
and the mutual benefits to be derived by the Loan Parties and Lender from a continuing relationship under the Loan Agreement and Loan
Documents and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto
agree as follows:

 

1.       Defined
Terms. Capitalized terms used in this Amendment which are defined in the Loan Agreement shall have the same meanings as defined
therein, unless otherwise defined herein.

2.        Amendment
to Loan Agreement. The Loan Agreement is hereby amended as of the date hereof as follows:

 

		(a)	Definition of Borrowing Base - Section 5(c). The definition of Borrowing Base in Section 5(c) of the Loan Agreement is hereby
amended and restated in its entirety, as follows:

 

(c)       The
term “Borrowing Base” as used herein shall mean the sum of the following:

 

(1)            
up to eighty-five percent (85%) of the unpaid face amount of Qualified Accounts (as defined below), PLUS

 

(2)            
the lesser of (I) the sum of (A) eighty-five percent (85%) of the Net Orderly Liquidation Value of all Eligible Inventory (as defined
below), which such Net Orderly Liquidation Value shall be reset on an annual basis in connection with the updated appraisals obtained
in connection herewith, plus (B) until June 1, 2022, at which time on such date this subclause (2)(I)(B) shall be $0, the lesser of (i)
$113,500, and (ii) twelve percent (12%) of the value of all Eligible WIP Inventory (with “Eligible WIP Inventory” being
Inventory that would have otherwise been Eligible Inventory but for the sole fact that it is work-in-process), or (II) $2,500,000, PLUS

 

    1

     

    

 

 

(3)            
an over-advance facility in the amount of Four Hundred Thousand and 00/100 Dollars ($400,000), which such amount shall, commencing
on June 1, 2022 and continuing on the first Business Day of each succeeding calendar month, reduce by $50,000 per month until such amount
reaches $0 (the “Over-Advance Facility”), PLUS 

 

(4)            
subject to the approval of Lender in its sole and unfettered discretion, an over-advance facility in an amount up to One Million
and 00/100 Dollars ($1,000,000.00) (the “2022 Over-Advance Facility”), LESS 

 

(5)            
the Borrowing Base Reserve (as defined below). 

 

(b)            
Loans and Other Financials Accommodations – Section 5 – Section 5 of the Loan Agreement is hereby amended
to add a new Section 5(j) immediately following Section 5(i), which such new Section 5(j) shall read as follows:

“(j)Borrower acknowledges that an advance under
the 2022 Over-Advance Facility in the amount of Two Hundred Thousand and 00/100 Dollars ($200,000.00) shall be disbursed on the Ninth
Amendment Effective Date. Thereafter, subsequent advances under the 2022 Over-Advance Facility, each of which shall be in amounts of not
less than One Hundred Thousand and 00/100 Dollars ($100,000.00), may be disbursed in the sole and unfettered discretion of Lender from
time to time upon the irrevocable request of Borrower.”

(c)       Fees
– Section 10 – Section 10 of the Loan Agreement is hereby amended to add a new Section 10(g) immediately following Section
10(f), which such new Section 10(g) shall read as follows:

“(g)2022 Over-Advance Facility Fees.
Borrower shall pay to Lender a non-refundable over-advance closing fee equal to $4,000 (the “2022 Over-Advance Facility Closing
Fee”), which such 2022 Over-Advance Facility Closing Fee shall be due and payable on the Ninth Amendment Effective Date. The
Borrower hereby further agrees to pay to the Lender the 2022 Over-Advance Facility Fee, due and payable on the first Business Day of each
month following the Ninth Amendment Effective Date during the Term.”

 

(d)       Definitions
- Section 22(p). Section 22(p) of the Loan Agreement is hereby amended to add the following definitions in the appropriate alphabetical
order:

“2022 Over-Advance
Facility” shall have the meaning set forth in Section 5(c).

 

“2022 Over-Advance
Facility Fee” means a non-refundable over-advance fee equal to such incremental amount that, when aggregated with the Interest Rate
on the outstanding balance of the 2022 Over-Advance Facility, is necessary to provide a monthly yield of one percent (1%) of the outstanding
balance of the 2022 Over-Advance Facility.

 

“Interest Rate”
means the rate of interest specified in Section 5(h) hereof. 

 

“Ninth Amendment
Effective Date” means April 5, 2022.

 

    2

     

    

 

3.       Amendment
Fee. Borrower agrees to pay Lender a non-refundable fee in the amount of $5,000.00 in consideration of the execution by Lender
of this Amendment (“Amendment Fee”). Such Amendment Fee shall be fully earned as of the date hereof and shall be due
and payable upon the earliest of (i) the expiration of the Term; (ii) any voluntary prepayment of the Revolving Loans resulting in a termination
of the Revolving Loans, (iii) the termination of the Loan Agreement, or acceleration of the Revolving Loans under Section 16 of the Agreement,
and (iv) the sale, assignment or transfer of all or any part of, or any interest in, Lender’s rights and benefits under the Loan
Agreement.

4.       Conditions
to Closing. The willingness of Lender to enter into this Amendment shall be subject to the condition precedent that Lender shall
have received all of the following, each in form and substance satisfactory to Lender:

 

		(a)	This Amendment properly executed and delivered,

 

(b)  
A Participation Agreement property executed and delivered by each of the parties thereto, and

 

(c)   
Payment by the Borrower of the 2022 Over-Advance Facility Closing Fee referenced in Section 2(g) above and any and all outstanding
reasonable out-of-pocket fees and expenses relating to the Loan Agreement and/or this Amendment incurred by the Lender, including, without
limitation, attorney’s fees and expenses.

 

5.        Representations
and Warranties. Each Loan Party represents and warrants to Lender that such Loan Party has the full power and authority to execute,
deliver and perform its obligations under, this Amendment and the execution and delivery of this Amendment have been duly authorized by
all necessary action of the stockholders, directors, members and managers, as applicable, of such Loan Party.

 

6.        Release
and Confirmation. Each Loan Party hereby (i) reaffirms that it remains indebted to Lender without defense, counterclaim or offset
and, assuming effectiveness of this Amendment, no default or Event of Default has occurred or exists under the Loan Documents, (ii) restates,
and reaffirms, all of its covenants, representations and warranties set forth in the Loan Documents to the same extent as if fully set
forth herein and each Loan Party hereby certifies that after giving effect to this Amendment, all such covenants, representations and
warranties are true and accurate as of the date hereof and (iii) acknowledges and warrants that it does not have any claims, actions or
causes of action whatsoever in law or in equity against Lender, its’ officers, directors, employees, agents, successors, subsidiaries,
related companies or attorneys (for the purpose of this paragraph, collectively referred to herein as the “Lenders”) or any
of them, in connection with or related to or arising from any and all transactions with Lenders, whether known or unknown, including,
but not limited to, the loans, through the date of this Amendment, and each Loan Party for good and valuable consideration hereby waives,
remises, releases and discharges any and all rights with respect to such claims, additions or causes of action, if any.

 

7.        Counterparts.
This Amendment may be executed in one or more counterparts, each of which when so executed and delivered shall be deemed to be an original
and all of which taken together shall constitute but one and the same agreement. Counterpart signature pages to this Amendment transmitted
by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic
means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery
of the paper document bearing an original signature.

 

    3

     

    

 

8.        References.
Upon and after the date of this Amendment all references to the Loan Agreement in the Loan Documents, or in any related document, shall
mean the Loan Agreement as amended by this Amendment. Except as expressly provided in this Amendment, the execution and delivery of this
Amendment does not and will not amend, modify or supplement any provision of, or constitute a consent to or a waiver of any noncompliance
with the provisions of the Loan Agreement, and, except as specifically provided in this Amendment, the Loan Agreement shall remain in
full force and effect in accordance with the respective terms thereof.

 

9.        Loan
Documents Ratified. This Amendment is executed as an instrument under seal and shall be governed by and construed in accordance
with the laws of the State of Connecticut without regard to its conflicts of law rules. All parts of the Loan Agreement and the other
Loan Documents, not affected by this Amendment are hereby ratified and affirmed in all respects, provided that if any provision
of the Loan Documents shall conflict or be inconsistent with this Amendment, the terms of this Amendment shall supersede and prevail.

10.       Costs
and Expenses. Each Loan Party hereby reaffirms its agreement under the Loan Agreement to pay or reimburse Lender on demand for
all costs and expenses incurred by Lender in connection with the Loan Documents, including without limitation all reasonable fees and
disbursements of legal counsel. Without limiting the generality of the foregoing, each Loan Party specifically agrees to pay all fees
and disbursements of counsel to Lender for the services performed by such counsel in connection with the preparation of this Amendment
and the documents and instruments incidental hereto. Each Loan Party hereby agrees that Lender may, at any time or from time to time in
its sole discretion and without further authorization by the Loan Party, make a loan to Borrower under the Loan Agreement, or apply the
proceeds of any loan, for the purpose of paying any such fees, disbursements, costs and expenses.

 

 

[SIGNATURES CONTINUED ON FOLLOWING PAGE]

 

 

 

 

    4

     

    

 

 

IN WITNESS WHEREOF, the parties have executed this
Amendment under seal as of the day and year first above written.

 

	 	BORROWER:	 
	 	 	 	 	 
	 	 	BLONDER TONGUE LABORATORIES, INC.	 
	 	 	 	 	 
	 	 	By:	 	 
	 	 	Name:	Eric Skolnik	 
	 	 	Title: 	Senior Vice President and Chief Financial Officer	 
	 	 	 	 	 
	 	OTHER LOAN PARTIES:	 
	 	 	 	 	 
	 	 	BLONDER TONGUE FAR EAST, LLC	 
	 	 	 	 	 
	 	 	By:	 	
    

     

	 	 	Name: 	Eric Skolnik	 
	 	 	Title: 	Senior Vice President and Chief Financial Officer	 
	 	 	 	 	 
	 	 	R. L. DRAKE HOLDINGS, LLC	 
	 	 	 	 	 
	 	 	By:	 	 
	 	 	Name:	Eric Skolnik	 
	 	 	Title: 	Senior Vice President and Chief Financial Officer	 
	 	 	 	  	 
	 	 	 	 	 
	 	LENDER:	 
	 	 	 	 	 
	 	 	MIDCAP BUSINESS CREDIT LLC	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	By:	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

 

 

 

 

 

 

[Ninth Amendment to Loan Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]